Publication & Citation Trends
Publications
0 total
THU-246 Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants
Cited by 0
Semantic Scholar
Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver
Cited by 0
Semantic Scholar
Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy
Cited by 0
Semantic Scholar
P174 Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial
Cited by 0
Semantic Scholar
83. Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a
Cited by 0
Semantic Scholar
WED-029 Patient-reported outcomes measuring an individual’s overall self- rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial
Cited by 0
Semantic Scholar
P-2191. Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study OA
Cited by 0
Semantic Scholar
WED-392 Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48weeks of bulevirtide monotherapy
Cited by 1
Semantic Scholar
Research Topics
Hepatitis B Virus Studies
(60)
Hepatitis C virus research
(56)
Liver Disease Diagnosis and Treatment
(34)
HIV/AIDS drug development and treatment
(15)
T-cell and B-cell Immunology
(11)
Affiliations
Université Claude Bernard Lyon 1
Lucile Packard Children's Hospital
Inserm
University of Pittsburgh
Chinese University of Hong Kong